<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00165334</url>
  </required_header>
  <id_info>
    <org_study_id>04-422</org_study_id>
    <nct_id>NCT00165334</nct_id>
  </id_info>
  <brief_title>Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer</brief_title>
  <official_title>Phase II Trial of Cetuximab Plus Vinorelbine in Previously Untreated Patients &gt; 70 With Advanced NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is it to determine how well patients with non-small cell lung&#xD;
      cancer respond to cetuximab plus vinorelbine. We would also like to determine the safety of&#xD;
      cetuximab plus vinorelbine in people 70 years of age or older with advanced non-small cell&#xD;
      lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Each cycle of study treatment is 21 days long. Cetuximab will be administered weekly&#xD;
           intravenously on days 1, 8 and 15 of the 21-day cycle.&#xD;
&#xD;
        -  Vinorelbine will be administered intravenously on days 1 and 8 of the 21-day cycle. On&#xD;
           the days when the patient receives both cetuximab and vinorelbine, cetuximab will be&#xD;
           given first.&#xD;
&#xD;
        -  For the first cycle only, the first infusion of cetuximab will be in a larger dose and&#xD;
           over a two-hour period of time. Beginning with the second treatment of cetuximab, the&#xD;
           patient will receive a smaller dose over a one-hour period of time.&#xD;
&#xD;
        -  For the first treatment of cetuximab, the patient will have their blood pressure,&#xD;
           temperature, breathing rate and heart rate (vital signs) taken at the following time&#xD;
           points: before the infusion, 1/2 hour into the infusion, at the end of infusion, and one&#xD;
           hour after the infusion.&#xD;
&#xD;
        -  For each subsequent cetuximab treatment, vital signs will be taken before each infusion&#xD;
           and one hour after the end of infusion. The patient will be required to remain in the&#xD;
           infusion room for one hour after the end of each cetuximab treatment for observation.&#xD;
&#xD;
        -  CT scan(s), MRI(s), and/or x-rays(s) of the site(s) of cancer will be done every six&#xD;
           weeks (every two cycles) while the patient is on the study to assess the extent of the&#xD;
           cancer and the response to treatment.&#xD;
&#xD;
        -  The duration of active participation in this study will depend on how the patients&#xD;
           non-small cell lung cancer responds to treatment and how well they tolerate the&#xD;
           treatment. The patient may receive up to six cycles of treatment with vinorelbine and&#xD;
           cetuximab. After these six cycles the patient may continue on cetuximab alone as long as&#xD;
           they are tolerating the drug and the cancer doesn't progress.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the overall response of cetuximab plus vinorelbine in patients 70 years or older with non-small lung cancer.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the safety of cetuximab plus vinorelbine in patients 70 years or older</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to determine the time to progression and survival rates of patients treated with cetuximab plus vinorelbine.</measure>
  </secondary_outcome>
  <enrollment>53</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine (Navelbine)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  70 years of age or greater&#xD;
&#xD;
          -  Stage IV or IIIB Non-small cell lung cancer&#xD;
&#xD;
          -  Must at least be able to walk and capable of taking care of yourself although unable&#xD;
             to carry out work activities&#xD;
&#xD;
          -  3 or more weeks since completing prior radiotherapy&#xD;
&#xD;
          -  3 or more weeks since prior major surgery&#xD;
&#xD;
          -  Blood tests that show your kidneys, liver and bone marrow to be working adequately&#xD;
&#xD;
          -  Life expectancy of 8 weeks or more&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior anticancer therapy within the past 3 years, including chemotherapy&#xD;
&#xD;
          -  Other currently active cancer&#xD;
&#xD;
          -  Uncontrolled Central Nervous System (CNS) problems&#xD;
&#xD;
          -  Pre-existing disease or abnormality of the nervous system&#xD;
&#xD;
          -  Hepatitis or Known HIV&#xD;
&#xD;
          -  Active uncontrolled infection&#xD;
&#xD;
          -  Incomplete healing from previous major surgery&#xD;
&#xD;
          -  Significant history of uncontrolled cardiac disease such as high blood pressure,&#xD;
             recent heart attack (within past 6 months), congestive heart failure, etc.&#xD;
&#xD;
          -  Prior therapy which targets the ErbB pathway&#xD;
&#xD;
          -  Prior severe infusion reaction to an antibody&#xD;
&#xD;
          -  Chemotherapy or other investigational agent not indicated in the study protocol&#xD;
             occuring at the same time as this study treatment&#xD;
&#xD;
          -  A medical condition that could make it unsafe for you to participate in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pasi A Janne, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferra√π F, Piazza E, Rosetti F, Clerici M, Bertetto O, Robbiati SF, Frontini L, Sacco C, Castiglione F, Favaretto A, Novello S, Migliorino MR, Gasparini G, Galetta D, Iaffaioli RV, Gebbia V; MILES Investigators. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003 Mar 5;95(5):362-72.</citation>
    <PMID>12618501</PMID>
  </reference>
  <reference>
    <citation>Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst. 1999 Jan 6;91(1):66-72.</citation>
    <PMID>9890172</PMID>
  </reference>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>July 21, 2009</last_update_submitted>
  <last_update_submitted_qc>July 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2009</last_update_posted>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>Vinorelbine</keyword>
  <keyword>Navelbine</keyword>
  <keyword>Previously untreated lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

